Orphanet Journal of Rare Diseases (Aug 2012)

Rescue of nonsense mutations by amlexanox in human cells

  • Gonzalez-Hilarion Sara,
  • Beghyn Terence,
  • Jia Jieshuang,
  • Debreuck Nadège,
  • Berte Gonzague,
  • Mamchaoui Kamel,
  • Mouly Vincent,
  • Gruenert Dieter C,
  • Déprez Benoit,
  • Lejeune Fabrice

DOI
https://doi.org/10.1186/1750-1172-7-58
Journal volume & issue
Vol. 7, no. 1
p. 58

Abstract

Read online

Abstract Background Nonsense mutations are at the origin of many cancers and inherited genetic diseases. The consequence of nonsense mutations is often the absence of mutant gene expression due to the activation of an mRNA surveillance mechanism called nonsense-mediated mRNA decay (NMD). Strategies to rescue the expression of nonsense-containing mRNAs have been developed such as NMD inhibition or nonsense mutation readthrough. Methods Using a dedicated screening system, we sought molecules capable to block NMD. Additionally, 3 cell lines derived from patient cells and harboring a nonsense mutation were used to study the effect of the selected molecule on the level of nonsense-containing mRNAs and the synthesis of proteins from these mutant mRNAs. Results We demonstrate here that amlexanox, a drug used for decades, not only induces an increase in nonsense-containing mRNAs amount in treated cells, but also leads to the synthesis of the full-length protein in an efficient manner. We also demonstrated that these full length proteins are functional. Conclusions As a result of this dual activity, amlexanox may be useful as a therapeutic approach for diseases caused by nonsense mutations.

Keywords